Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A CDISC Implementation Maturity Model: Viewpoint on Moving Beyond Isolated Technical Fixes in Regulatory Submissions.

Created on 14 Nov 2026

Authors

Akash Kamble

Published in

JMIR medical informatics. Volume 14. Pages e105990. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

The Clinical Data Interchange Standards Consortium (CDISC) has become the cornerstone of regulatory data submission frameworks for pharmaceutical and biotechnology organizations worldwide. Although the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency require standardized study data, clinical data teams continue to face persistent operational barriers, including controlled terminology misuse, ambiguity in mapping protocol-specific data to domains, insufficient validation automation, and conformance findings that add review cycles. This Viewpoint argues that sustainable improvement in CDISC submission quality requires organizations to move beyond isolated technical fixes toward a staged, systematically assessable model of implementation maturity and proposes the CDISC Implementation Maturity Model (CIMM) as a framework for that assessment. Technical fixes-domain selection discipline, controlled terminology governance, template-based and metadata-driven automation, and multilayered validation-matter, but organizations that treat them as independent problems tend to underinvest in the institutional structures that make any one fix durable. Adapted from staged capability maturity modeling and established maturity model design procedures, the CIMM characterizes organizational CDISC capability across 5 dimensions-process standardization, automation coverage, terminology governance, validation integration, and institutional knowledge distribution-and 5 maturity levels, from Ad Hoc to Optimizing. Each of the 25 level-dimension cells carries an observable indicator, and an organization's overall maturity is set by its weakest dimension. The framework is offered as a conceptual synthesis; its level definitions and the submission outcomes associated with each level are hypotheses to be tested, not validated findings. Submissions that are efficient to produce and more likely to clear regulatory review on the first attempt are more plausibly reached through the deliberate, staged development of the 5 capability dimensions the CIMM describes than through any single tool or technique. Testing the reliability of CIMM level assignment and its association with observed submission outcomes is the necessary next step.

PMID:
43024851
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement